Systematic screening identifies USP20 as an accelerator of metabolic dysfunction-associated steatotic liver disease via driving de novo lipogenesis
Pharmacological Research · 2026
DOI: 10.1016/j.phrs.2026.108406 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacological Research, 2026. Verfasst von Xiaoxuan Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of Chin…. Hauptthemen laut MEDLINE: Lipogenesis, Ubiquitin Thiolesterase, Non-alcoholic Fatty Liver Disease. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND AND AIMS: Excessive hepatic lipid production drives disrupted lipid homeostasis. Although deubiquitinases have emerged as key modulators of metabolic enzymes, their involvement in de novo lipogenesis (DNL) remains elusive. RESULTS: Hepatic USP20 is identified by the multi-screening system based on biological assays of the constructed 105 DUB-plasmids library, combined with transcript analysis of multi-species with MASLD. USP20 activates the DNL pathway through multi-omics integrated analysis and isotope-metabolic flux tracing. The most potential USP20-interacting protein, FASN is screened by IP-MS. USP20 interacts with FASN and deubiquitinates K48-linked FASN to block proteasome-mediated degradation. Consequently, downstream lipogenic genes are activated in DNL pathway and excessive PA occurs in hepatocytes. Through rank by virtual screening, based on the pocket alignment of USP20 and molecular dynamics simulation, the small molecule compound-C2 screened markedly inhibits USP20, thereby suppressing DNL to alleviate MASLD. CONCLUSIONS: Our finding establishes USP20 as a central driver of DNL via deubiquitinating FASN. A promising therapeutic strategy targeting-USP20 is provided for MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmacy, Anhui Medical University, Hefei, China.
- Innovation Center for AI and Drug Discovery, School of Pharmacy, East China Normal University, Shanghai 200062, China; East China University of Science and Technology, Shanghai, China.
- Department of Endocrinology, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, He…
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, China; State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China; NHC Key…
- College of Food and Biological Engineering, Hefei University of Technology, Hefei, China. Electronic address: zhangshuang@hfut.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ma, X., Qin, W., Feng, Z., Luan, N., Pan, R., Diao, Y., Yin, Z., Xu, S., Ge, J., Zhang, S., & Duan, Y. (2026). Systematic screening identifies USP20 as an accelerator of metabolic dysfunction-associated steatotic liver disease via driving de novo lipogenesis. Pharmacological Research. https://doi.org/10.1016/j.phrs.2026.108406
Vancouver
Ma X, Qin W, Feng Z, Luan N, Pan R, Diao Y, et al. Systematic screening identifies USP20 as an accelerator of metabolic dysfunction-associated steatotic liver disease via driving de novo lipogenesis. Pharmacological Research. 2026. doi:10.1016/j.phrs.2026.108406
BibTeX
@article{Ma2026,
author = {Ma, Xiaoxuan and Qin, Weiwei and Feng, Zian and Luan, Nengneng and Pan, Ruru and Diao, Yanyan and Yin, Zequn and Xu, Suowen and Ge, Junbo and Zhang, Shuang and Duan, Yajun},
title = {Systematic screening identifies USP20 as an accelerator of metabolic dysfunction-associated steatotic liver disease via driving de novo lipogenesis},
journal = {Pharmacological Research},
year = {2026},
doi = {10.1016/j.phrs.2026.108406}
}
EUVIMED